Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration

Survey of Ophthalmology
Irmela MantelEric H Souied

Abstract

The introduction of antivascular endothelial growth factor agents such as ranibizumab and aflibercept has revolutionized the management of neovascular age-related macular degeneration. A number of randomized clinical trials have shown that ranibizumab and aflibercept produce similar efficacy and safety outcomes. Most of the switching studies published to date show that efficacy benefits are uncontrolled, retrospective trials with limitations in terms of their selection, monitoring, numbers, and assessment criteria. Based on the published literature to date, we propose arguments for and against switching antivascular endothelial growth factor agents, provide our own perspective on this topic, and suggest a focus for future research.

Citations

Oct 22, 2019·Journal of Cellular and Molecular Medicine·Janusz BlasiakKai Kaarniranta
Feb 16, 2019·Scientific Reports·Byung Ju JungWon Ki Lee
May 4, 2020·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Jae Hui KimDong Won Lee
Nov 28, 2020·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Marta ZolaIrmela Mantel
Dec 19, 2020·Ophthalmic Surgery, Lasers & Imaging Retina·Phoebe L MellenMichael A Klufas
Aug 3, 2020·Asia-Pacific Journal of Ophthalmology·Ching-Yu ChengTien Yin Wong
Apr 14, 2021·The British Journal of Ophthalmology·Louisa Maria BulirschFrank G Holz
Sep 17, 2021·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·E MoretI Mantel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.